PMID- 29676236
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20191210
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 17
IP  - 4
DP  - 2018
TI  - Monoamine Involvement in the Antidepressant-Like Effect of beta-Caryophyllene.
PG  - 309-320
LID - 10.2174/1871527317666180420150249 [doi]
AB  - BACKGROUND: Major depressive disorder is a psychiatric disorder that affects 4.4% 
      of the population worldwide. Although the majority of antidepressant drugs 
      ameliorate depressive symptoms, there is still a need for safer and more 
      effective antidepressant. OBJECTIVE: Evaluate the antidepressant-like activity of 
      sesquiterpene compound beta-caryophyllene (BCP) for the possible contribution of the 
      monoamine and hippocampal levels of brain-derived neurotrophic factor (BDNF). 
      METHODS: Male albino Swiss mice were subjected to the forced swimming test after 
      acute treatment and to the tail suspension test after repeated treatment. 
      Hippocampal levels of BDNF were assayed by enzyme-linked immunosorbent assay. 
      RESULTS: The anti-immobility effect of BCP was reverted by pretreatment with an 
      inhibitor of catecholamine synthesis alpha-methyl-p-tyrosine (100 mg/kg, i.p.), 
      alpha2-adrenergic antagonist yohimbine (1 mg/kg, i.p.), and beta-adrenergic antagonist 
      propranolol (2 mg/kg, i.p.), but not by pretreatment with either alpha1-adrenergic 
      antagonist prazosin (1 mg/kg, i.p.) or 5-HT1A antagonist NAN-190 (0.5 mg/kg, 
      i.p.), thereby suggesting the involvement of alpha2 and beta-adrenergic receptors, but 
      not of the alpha1-adrenergic and 5-HT1A serotonergic receptors, in BCP's 
      antidepressive-like activity. Furthermore, BCP increased BDNF levels in the 
      hippocampus after 14 days of treatment. No treatments in this study altered 
      locomotor activity in the open field test. CONCLUSION: This study provides a new 
      mechanism of BCP-induced antidepressant-like effect mediated by some sub-types of 
      catecholaminergic neurotransmitter system that could be a candidate for clinical 
      tests of new treatments for depressive disorders.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - de Oliveira, Danillo Ramos
AU  - de Oliveira DR
AD  - Programa de Pos-Graduacao em Ciencias Farmaceuticas, Faculdade de Farmacia, 
      Universidade Federal de Goias, Goiania, GO, Brazil.
FAU - da Silva, Dayane Moreira
AU  - da Silva DM
AD  - Programa de Pos-Graduacao em Ciencias Biologicas, Instituto de Ciencias 
      Biologicas, Universidade Federal de Goias, Goiania, GO, Brazil.
FAU - Florentino, Iziara Ferreira
AU  - Florentino IF
AD  - Departamento de Ciencias Fisiologicas, Instituto de Ciencias Biologicas e da 
      Saude, Universidade Federal Rural do Rio de Janeiro, Seropedica, RJ, Brazil.
FAU - de Brito, Adriane Ferreira
AU  - de Brito AF
AD  - Programa de Pos-Graduacao em Ciencias Biologicas, Instituto de Ciencias 
      Biologicas, Universidade Federal de Goias, Goiania, GO, Brazil.
FAU - Fajemiroye, James Oluwagbamigbe
AU  - Fajemiroye JO
AD  - Programa de Pos-Graduacao em Ciencias Biologicas, Instituto de Ciencias 
      Biologicas, Universidade Federal de Goias, Goiania, GO, Brazil.
FAU - da Silva, Daiany Priscilla Bueno
AU  - da Silva DPB
AD  - Programa de Pos-Graduacao em Ciencias Biologicas, Instituto de Ciencias 
      Biologicas, Universidade Federal de Goias, Goiania, GO, Brazil.
FAU - da Rocha, Fabio Fagundes
AU  - da Rocha FF
AD  - Departamento de Ciencias Fisiologicas, Instituto de Ciencias Biologicas e da 
      Saude, Universidade Federal Rural do Rio de Janeiro, Seropedica, RJ, Brazil.
FAU - Costa, Elson Alves
AU  - Costa EA
AD  - Departamento de Farmacologia, Instituto de Ciencias Biologicas, Universidade 
      Federal de Goias, Goiania, GO, Brazil.
FAU - Galdino, Pablinny Moreira
AU  - Galdino PM
AD  - Centro de Ciencias Biologicas e da Saude, Universidade Federal do Oeste da Bahia, 
      Barreiras, BA, Brazil.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Antidepressive Agents)
RN  - 0 (Polycyclic Sesquiterpenes)
RN  - 0 (Sesquiterpenes)
RN  - 333DO1RDJY (Serotonin)
RN  - BHW853AU9H (caryophyllene)
MH  - Animals
MH  - Antidepressive Agents/*therapeutic use
MH  - Behavior, Animal/*drug effects
MH  - Depression/drug therapy
MH  - Depressive Disorder, Major/*drug therapy
MH  - Hindlimb Suspension
MH  - Motor Activity/drug effects
MH  - Polycyclic Sesquiterpenes
MH  - Serotonin/pharmacology
MH  - Sesquiterpenes/*pharmacology
OTO - NOTNLM
OT  - Antidepressant-like effect
OT  - Hippocampal levels
OT  - Major depressive disorder
OT  - behavioral test
OT  - monoamines
OT  - beta-caryophyllene.
EDAT- 2018/04/21 06:00
MHDA- 2019/08/14 06:00
CRDT- 2018/04/21 06:00
PHST- 2017/06/19 00:00 [received]
PHST- 2018/02/11 00:00 [revised]
PHST- 2018/04/16 00:00 [accepted]
PHST- 2018/04/21 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
PHST- 2018/04/21 06:00 [entrez]
AID - CNSNDDT-EPUB-89887 [pii]
AID - 10.2174/1871527317666180420150249 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2018;17(4):309-320. doi: 
      10.2174/1871527317666180420150249.